Answers are grounded in this paper and cite their sources.
Network meta-analysis evaluates efficacy of targeted therapies for atopic dermatitis, suggesting a need for head-to-head trials.
Among currently approved targeted systemic therapies, upadacitinib 30 mg once daily ranked highest across all evaluated efficacy outcomes. However, these findings are derived primarily from indirect comparisons, and head-to-head randomized trials are needed to confirm the relative effectiveness of these therapies.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: